MARKET

TVTX

TVTX

Travere Therapeutics Inc
NASDAQ
22.91
-0.81
-3.41%
After Hours: 23.10 +0.19 +0.83% 19:17 02/14 EST
OPEN
24.00
PREV CLOSE
23.72
HIGH
24.14
LOW
22.82
VOLUME
1.47M
TURNOVER
--
52 WEEK HIGH
25.29
52 WEEK LOW
5.12
MARKET CAP
1.97B
P/E (TTM)
-5.0286
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TVTX last week (0210-0214)?
Weekly Report · 12h ago
Travere Therapeutics price target raised to $47 from $45 at Guggenheim
TipRanks · 3d ago
TRAVERE THERAPEUTICS INC <TVTX.O>: GUGGENHEIM RAISES TARGET PRICE TO $47 FROM $45
Reuters · 3d ago
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
NASDAQ · 4d ago
Evercore ISI Keeps Their Buy Rating on Travere Therapeutics (TVTX)
TipRanks · 4d ago
Travere Therapeutics: Strong Buy Rating Driven by Filspari’s $1 Billion Market Potential in FSGS
TipRanks · 4d ago
TRAVERE THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 5d ago
Travere Therapeutics Is Maintained at Sector Outperform by Scotiabank
Dow Jones · 5d ago
More
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).

Webull offers Travere Therapeutics Inc stock information, including NASDAQ: TVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVTX stock methods without spending real money on the virtual paper trading platform.